Current Report Filing (8-k)
November 13 2020 - 5:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 11, 2020
Summit Therapeutics Inc.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
Delaware
|
001-36866
|
Pending
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
One Broadway, 14th Floor, Cambridge, MA
|
02142
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s Telephone Number, Including
Area Code: 617-514-7149
Not Applicable
|
(Former Name or Former Address, If Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
Common stock, $0.01 par value per share
|
SMMT
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On November 11, 2020, the Board of Directors
(the “Board”) of Summit Therapeutics Inc. (the “Company”) elected Dr. Mahkam Zanganeh to serve as a member
of the Board.
As previously reported, on November 6, 2020
the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Mahkam Zanganeh Revocable
Trust (the “Trust”) pursuant to which the Trust acquired 149,701 shares of the Company’s common stock, par value
$0.01 per share (the “Common Stock”) for an aggregate purchase price of approximately $500,000 in a private placement.
In connection with the foregoing transaction, the Company entered into a Registration Rights Agreement with the Trust and another
investor, dated November 6, 2020, pursuant to which the Company agreed to prepare and file with the SEC a registration statement
within 60 days that would register for resale all Registrable Securities (as defined in the Registration Rights Agreement). In
accordance with the foregoing, subject to certain terms and conditions, the shares of Common Stock issued to the Trust pursuant
to the Purchase Agreement shall become eligible for resale. As trustee of the Trust, Dr. Zanganeh may be deemed to beneficially
own the securities of the Company owned by the Trust.
Until June 29, 2020, Maky Zanganeh & Associates,
Inc. (“MZA”) had performed certain consultancy services for Summit Therapeutics plc (“Old Summit”) (the
predecessor entity to the Company prior to the Company’s domestication as a Delaware corporation) in accordance with a Consulting
Agreement by and between Old Summit and MZA (the “Consulting Agreement”), which was terminated on such date by mutual
agreement in accordance with its terms. Pursuant to the Consulting Agreement, MZA received aggregate payments of approximately
$450,000 and an allotment of warrants to purchase ordinary shares in Old Summit.
The warrants granted to MZA were transferred to Dr. Zanganeh, other than a small number of warrants which were transferred to an
employee of MZA. Dr. Zanganeh is the sole stockholder of MZA. Except as described herein, there are no transactions with the Company
in which Dr. Zanganeh has an interest requiring disclosure pursuant to Item 404(a) of Regulation S-K.
On November 12, 2020, Ventzislav Stefanov resigned
from the Company both in his capacity as Executive Vice President of the Company and President of Discuva, and as a member of the
Board. He will continue to work with the Company through mid-December 2020 to facilitate the transition of his responsibilities
as an officer. His resignation was not due to any disagreement with the Company regarding the Company’s operations, policies
or practices.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
SUMMIT THERAPEUTICS INC.
|
|
|
|
|
Date: November 12, 2020
|
By:
|
/s/ Michael Donaldson
|
|
|
Michael Donaldson
|
|
|
Chief Financial Officer
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024